Sunday 4 October 2026
Afternoon EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
Science

Obesity drug retatrutide shows unprecedented weight loss in late-stage trial

Patients lost up to 30% of body weight over two years, with additional benefits for knee pain and sleep apnea

By LineZotpaper
Published
Read Time2 min
Researchers have published late-stage clinical trial data for retatrutide, the latest obesity drug expected to be the most powerful yet, showing patients on the highest dose lost an average of 25% of their body weight after 80 weeks, with some losing 30% or more over two years. The results, published today in the New England Journal of Medicine, also revealed significant improvements in knee pain, sleep apnea, and cardiometabolic health markers.

The phase 3 trial, which began in 2023, enrolled 2,339 participants across 131 sites in 11 countries. Participants were divided into four nearly equal groups receiving either 4 mg, 9 mg, 12 mg of retatrutide, or a placebo. The average starting weight was around 113 kilograms (250 pounds) with an average body mass index (BMI) of 40.

After 80 weeks, patients on the highest dose lost an average of 25% of their body weight, and those in an extension period reached an average loss of 30% after 104 weeks. More than a third of retatrutide-treated participants lost 30% or more of their weight.

The drug also showed efficacy in treating obesity-related conditions. Among 574 participants with knee osteoarthritis, retatrutide reduced knee pain by up to 62%. In 243 participants with obstructive sleep apnea, the drug reduced sleep apnea events per hour by up to 57%. Across all groups, cardiometabolic measurements improved, including blood pressure, triglycerides, and low-density lipoprotein (LDL) cholesterol. At enrollment, more than a third of participants had prediabetes, but by the end of the study, the condition resolved in more than 90% of those cases.

§

Analysis

Why This Matters

  • Retatrutide's weight loss results surpass those of existing GLP-1 drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), potentially offering a new treatment option for millions with obesity
  • The drug's additional effects on knee osteoarthritis pain and sleep apnea could address common, debilitating complications of obesity, reducing the need for surgery or continuous positive airway pressure (CPAP) devices
  • Widespread use could significantly reduce healthcare costs tied to obesity-related diseases, though affordability and insurance coverage remain key questions

Background

Obesity affects over 650 million adults globally and is a leading cause of diabetes, heart disease, and joint problems. The market for weight-loss drugs has grown rapidly in recent years, with GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide generating billions in sales. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, which researchers believe amplifies its weight-loss effects. Eli Lilly, the maker of retatrutide, is expected to seek regulatory approval after these phase 3 results.

Key Perspectives

Patients with obesity: Retatrutide offers significant, sustained weight loss and relief from comorbidities like knee pain and sleep apnea, potentially improving quality of life and reducing reliance on other treatments. Healthcare providers: Doctors may have a new, more potent tool for managing obesity as a chronic disease, but will need to weigh benefits against side-effect profiles and cost. The drug's efficacy in resolving prediabetes in most participants is particularly promising for preventing type 2 diabetes. Critics and payers: Insurers and public health systems may balk at high list prices for these drugs, and questions about long-term safety beyond two years remain unanswered. Critics also point to the need for comprehensive obesity care that includes diet and exercise counseling.

What to Watch

  • Approval timelines and pricing decisions from Eli Lilly and regulators
  • Real-world uptake and insurance coverage decisions in major health systems
  • Long-term safety data, especially regarding gastrointestinal side effects or pancreatic and thyroid risks seen with other GLP-1 drugs

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workReport an errorSubscribe